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Abstract
We aimed to investigate whether infection with high-risk (HR)Background: 
types of human papilloma virus (HPV) or HPV-associated cervical disease
were associated with preterm birth (<37 weeks gestation). In a sub-group of
younger women who were eligible for the HPV vaccine, we aimed to
determine whether prior vaccination against the specific HPV-types,
HPV-16 and -18 modified preterm birth risk.
This was a data-linkage study, which linked HPV-associated viralMethods: 
and pathological information (from the Scottish HPV Archive) from women
aged 16-45 years to routinely collected NHS maternity- and
hospital-admission records from 1999–2015. Pregnancy outcomes from
5,598 women with term live birth (≥37 weeks gestation, n=4,942), preterm
birth (<37 weeks gestation, n=386) or early miscarriage (<13 weeks
gestation, n=270). Of these, data from HPV vaccine-eligible women
(n=3,611, aged 16-25 years) were available, of whom 588 had been
vaccinated. HPV-associated disease status was defined as: HR
HPV-positive no disease, low-grade abnormalities or high-grade disease.
High-grade HPV-associated cervical disease was associated withResults: 
preterm birth (odds ratio=1.843 [95% confidence interval 1.101–3.083],
p=0.020) in adjusted binary logistic regression analysis, in all women, but
there were no associations with HR HPV-infection alone or with low-grade
abnormalities. No associations between any HPV parameter and preterm
birth were seen in vaccine-eligible women, nor was there any effect of prior
vaccination.
 HPV-associated high-grade cervical disease was associatedConclusions:
with preterm birth, but there were no associations with HR HPV-infection or
low-grade cervical disease. Thus HPV-infection alone (in the absence of
cervical disease) does not appear to be an independent risk factor for
preterm birth. For women who have undergone treatment for CIN and
become pregnant, these results demonstrate the need to monitor for signs
of preterm birth.
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Introduction
Human papillomavirus (HPV) is a sexually transmissible virus 
that infects cervical cells. Normally, the virus is cleared by the 
immune system, becoming undetectable within two years1. 
Persistent HPV infection causes pre-cancerous cervical intraepi-
thelial neoplasia (CIN); left untreated, CIN can develop into 
cervical cancer2. Over 200 HPV types exist, of which 14 are 
oncogenic or high-risk (HR). Two such HR types, HPV-16 and 
-18, are responsible for 70–80% of invasive cervical cancers3. 
Treatment of CIN and cervical cancer is by removal of the 
abnormal cervical cells4. 
The cervix is important for maintenance of pregnancy, with 
barrier and immune mechanisms that protect the growing 
foetus5. HPV-infection may alter cervical function, possibly 
increasing the risk of intrauterine infections6 and subsequent 
complications such as preterm birth7 or miscarriage8.
The relationships between HPV infection and pregnancy out-
comes are unclear. Some studies have shown no association9,10, 
whereas others have suggested that HPV-infection, cervical 
disease and/or its treatment are associated with adverse 
pregnancy outcomes, such as miscarriage11, premature preterm 
rupture of membranes (PPROM)12 or spontaneous preterm 
birth13,14.
We performed a data-linkage cohort study, linking women with 
HPV viral and pathological data with their own pregnancy 
records. The aims for this study were to determine whether 
HR HPV-infection, specific HR HPV types, or the presence of 
HPV-associated cervical disease were associated with preterm 
birth (<37 weeks gestation), early miscarriage (<13 weeks 
gestation) or stillbirth (pregnancy loss at ≥24 weeks gestation) 
and whether previous vaccination against HPV-16/18 affected 
these outcomes.
Methods
Study background
This study was a data-linkage study, linking data from 
women with HPV viral and pathological data contained 
within the Scottish HPV Archive (see below) with their own 
pregnancy records. After data-cleaning, the retrospective data 
from the women in the resulting cohort were analysed for 
associations between the HPV viral/pathology parameters and 
adverse pregnancy outcomes: preterm birth (<37 weeks gesta-
tion), early miscarriage (<13 weeks gestation) and stillbirth 
(≥24 weeks gestation). The study population for whom data 
were obtained and linked were women who had samples and 
data within the Scottish HPV Archive and who had had details of 
pregnancy outcomes.
Eligibility criteria
Women whose HPV-infection status was known at the time of 
birth were included. As HPV is usually cleared within 2 years1 
and women are advised to delay their next scheduled cervical 
smear until at least 12 weeks postnatally4, women who had a 
pregnancy up to 1 year prior to the cytology date were also 
included. In women who had had more than one pregnancy, the 
pregnancy outcome nearest the cytology date was included.
Exclusion criteria for the study were: Multiple (twin) pregnan-
cies, as these babies are more often routinely delivered preterm; 
therapeutic terminations, ectopic pregnancies and trophoblastic 
disease were also excluded.
Definition of terms
The definitions for pregnancy outcomes were: Term live 
births were women who had a live birth at term (≥37 weeks 
gestation); All preterm births were women with births before 
37 weeks’ gestation including miscarriages of ≥13 weeks 
gestation; Spontaneous preterm births were women with births 
prior to 37 weeks’ of gestation, including those with PPROM 
and miscarriages of ≥13 weeks gestation, but excluding 
iatrogenic preterm births (those delivered by elective caesarean 
section or those which were induced); Early Miscarriage was 
any spontaneous pregnancy loss before 13 weeks’ gestation; 
Stillbirth was defined as any pregnancy loss after 24 weeks’ 
gestation.
Sources of patient information used for the data-linkage
Scottish HPV Archive. Scotland has a cervical screening 
programme with population coverage of around 70%15. Until 
June 2016, women aged 20–60 years were screened; thereafter 
the age-range was 25–65 years. In September 2008, a routine, 
school-based HPV vaccination programme for girls aged 
11–13 years was introduced, with a “catch-up” immunisation 
programme for girls aged 13–17 years16. In 2009, the Scottish 
HPV Archive was established as a biobank for HPV-associated 
research. It is a collection of collections which includes residual 
cervical samples from women attending routine cervical screen-
ing and colposcopy clinics, from the year 2000 to the present. 
Many samples within the Archive have a patient identifier 
(community health index [CHI] number) and associated 
clinical, cytology and histology results, obtained from the 
Scottish Cervical Cytology Recall System (SCCRS). SCCRS 
is the national IT system that supports the Scottish cervical 
screening program and contains a woman’s entire screening 
record4. A number of samples in the Archive are annotated with 
HPV status as a consequence of immunisation surveillance 
and specific research projects17,18, using different HPV assays 
depending on the nature and objectives of the research projects 
(Table 1). At the time of data-linkage the Scottish HPV archive 
contained 31,320 records from women (aged 20–60 years). The 
Scottish HPV Archive has generic Research Tissue Bank 
approval from the East of Scotland Research Ethics Service 
(REC Ref 11/AL/0174) and is registered with Lothian NRS 
Bioresource. Approval for use of HPV data was given by the 
Archive Steering Committee (HPV Archive Application Ref 
0018).
Scottish Morbidity Record (SMR)02. SMR02 is the Maternity 
Inpatient and Day Case Dataset19, held by the Information Serv-
ices Division (ISD) of the National Health Service (NHS) 
National Services Scotland (NSS) and covers maternity 
admissions in Scotland. SMR02 includes over 98% of deliveries, 
as less than 2% of deliveries occur at home. A quality assurance 
audit of SMR02 showed that accuracy of the records exceeded 
90%, when compared with corresponding written medical 
records20. 
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SMR01. SMR01 is the General/Acute Inpatient and Day Case 
Dataset, held by NHS NSS ISD, and covers hospital admissions 
in Scotland19. Audit of SMR01 found that accuracy of clinical 
data was more than 89%, when compared with written medical 
records22. Miscarriage data were obtained from both SMR01 
and SMR02. If an SMR01 record had no corresponding SMR02 
record, we assumed that the miscarriage occurred before 
13 weeks’ gestation, as it is usual practice for pregnancies to be 
registered on SMR02 before 13 weeks gestation23. Scottish birth 
statistics from the Scottish population, obtained from SMR02 
and SMR01, are available from the NHS NSS ISD website, 
Births in Scottish Hospitals23.
Miscarriage may occur before the mother is aware she is 
pregnant, and is often managed in an outpatient or general 
practice setting23,24; such cases would not generate a hospital 
or maternity record. Women admitted to a hospital ward via an 
emergency or gynaecology department or early pregnancy unit 
generate an SMR01 record; women admitted to a maternity unit 
generate an SMR02 record. Between 1998 and 2016, the 
population rate of miscarriages managed in Scottish hospitals 
(data from SMR01 and SMR02) fell from 7.0 to 4.4 per 
1000 women aged 15–44 per year23. From these numbers, the 
percentage of miscarriages in the Scottish birth data for each 
year was calculated as:
miscarriages
miscarriages number for each year
Percentage of  miscarriages Number of  given for each year
Number of  of  births 
=
+
From this calculation, for the years 1998–2016 the percentage 
of miscarriages approximated to 8.0- 12.0% of all births per 
year.
National Records of Scotland (NRS). This resource hold the 
records of stillbirths and infant deaths in Scotland25.
Approval for use of data
Approval for use of NHS NSS and NRS data was obtained from 
the NHS Privacy Advisory Committee (PAC 74/14). Approval 
for linkage of previous unlinked datasets was given by the NHS 
Scotland National Caldicott Guardian Forum (Ref 2015-19). 
The linked dataset was analysed within the NHS National Safe 
Haven, provided by NHS Research Scotland26. The Safe Haven 
is a remote server through which the researcher accesses the 
health data and services to enable research while protecting the 
confidentiality of the data. Data remains under the control of 
the NHS and complies with legislative and NHS policies. The 
linked dataset is archived within the Safe Haven and is available 
by application to NHS Scotland via the electronic Data Research 
and Innovation Service (eDRIS)27, within the Farr Institute for 
Health Informatics Research.
Data extraction
The data-linkage and -cleaning processes are summarised in 
Figure 1. Data were transferred between the Scottish HPV 
Archive and eDRIS, where data-linkage was performed. From all 
the women’s records within the Scottish HPV Archive (N=31,320), 
those who had had pregnancies recorded in SMR02, SMR01 and 
NRS were identified by the CHI number. Coded identification 
numbers of women with pregnancy records were sent back to the 
Scottish HPV Archive (n=10,572), from where HPV-genotype, 
cytology date and result, histology date and result, vaccination 
date and dosage were collated. These data are denoted as ‘HPV 
viral/pathology data’. The HPV viral/pathology data and 
corresponding SMR02, SMR01 and NRS records were collated, 
anonymised and placed in the Safe Haven. For data cleaning 
and analysis, only the Safe Haven and the linked datasets were 
accessed.
Pregnancy admission records from SMR02, SMR01 and NRS 
records for women in the Scottish HPV Archive were received 
from January 1981 to August 2015. Many of the older women 
within the Scottish HPV Archive had their pregnancies before 
their HPV-infection status was known and so were excluded. 
Records in the Scottish HPV Archive started in 2000, so 
pregnancy admissions before 1999 were removed; therefore, the 
time-period for this study was 1999–2015. Duplicate records 
were removed. Information from multiple admissions per 
pregnancy outcome were condensed into one record. The 
variables obtained from SMR01, SMR02, NRS records and the 
Scottish HPV Archive are presented in Table 1, together with 
details of data coding and cleaning. Pregnancy records were 
coded without reference to HPV-infection status. The proportions 
of women with specific pregnancy outcomes within our final 
cohort was compared with that of the Scottish population23 to 
determine how representative our cohort was of the Scottish 
population.
Classification of individuals within the dataset
HPV-infection status of each woman was defined as HR HPV- 
positive if there was a positive result for at least one HR HPV 
type (Table 1). Infections with a mixture of HPV types were 
common. Low-risk HPV-positive samples (Table 1) and HPV- 
negative results were considered HR HPV negative.
Women were classed as HPV-16/18-positive if they had samples 
containing HPV-16 and/or HPV-18, irrespective of other types 
present. Women were classed as non-16/non-18 HR HPV-positive 
if they had samples that were negative for HPV-16 or HPV-18 but 
contained other known HR HPV types.
HPV-associated cervical disease was classed as: HR HPV-
negative; HR HPV-positive no disease (i.e. normal cytology); 
low-grade abnormalities (borderline/mild dysplasia, normal/
low-grade histology, CIN1) or high-grade disease (high-grade 
dysplasia, CIN2, CIN3, CGIN, cancer, high-grade intraepithelial 
lesion).
HPV vaccination status. Some women had received the bivalent 
HPV vaccine17 (1–3 doses) against HPV-16 and -18. Vaccine- 
eligible women were classified as: those who had been 
vaccinated, those eligible (by age) but unvaccinated, or those 
eligible but whose vaccination status was unavailable; women 
born before 1990 were too old to have been eligible for 
vaccination.
Scottish National guidelines require over 90% of women with 
HPV-associated high-grade cervical disease to have undergone 
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Figure 1. Summary of data-linkage and -cleaning processes.
excisional treatment4, but data for the specific treatments used were 
not available.
Determining cohort reliability
To determine how representative our cohort was of the 
Scottish population, the proportions of women with specific 
HPV viral/pathology parameters within our final cohort, were 
compared with a recent HPV prevalence study in women attend-
ing screening in Scotland28, as HPV results are not recorded 
as part of routine cervical screening. Pathology data (low- and 
high-grade disease) were compared with data from ISD29.
Potential confounders for pregnancy outcomes were obtained 
from SMR02 and SMR01: ethnicity, parity, Scottish Index of 
Multiple Deprivation (SIMD), smoking history and during 
current pregnancy, diabetes (pre-existing and gestational) and 
hypertension (any). Coding and definitions for these variables 
are shown in Table 1. Continuous variables obtained were 
maternal age and maternal BMI. Neither variable was normally 
distributed, nor was any transformation able to normalise the 
data. Maternal age (range 16–45 years) was severely skewed, with 
62.9% of women in our cohort aged <25 years. As we wished 
to investigate the effects of vaccination, and the vaccine-eligi-
ble women were aged <25 years, we chose 20 years as the age 
cut-off point for the analyses, comparing those aged <20 years 
with  those >20 years. Maternal BMI data were categorised: 
underweight (BMI <19.9), normal (BMI 20.0–24.9), overweight 
(BMI 25.0–29.9) and obese (BMI ≥30.0).
Statistical analysis
All statistical analyses were carried out using SPSS v22 
(© IBM Corporation, USA). Missing data analysis (Table 2) 
of the cleaned full dataset was carried out using the ‘Multiple 
Imputation’ function, which runs regression models of existing 
data to replace missing data: i.e. the programme looks at patterns 
of the data available and makes probability judgements (impu-
tations) to give estimates of the missing data. Data was missing 
for Scottish Index of Material Deprivation (SIMD), ethnicity, 
parity, hypertensive disorder, current smoking, smoking history, 
diabetes and maternal BMI (Table 3). Variables were imputed 
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Table 2. Missing data analysis. Table shows the results of the missing data 
analysis (number of valid variables, number and percent missing variables) for 
all variables with missing data.
Variables with missing data Valid Missing Total N
N Percent N Percent
No. cases with complete data 3,123 55.8% 2,475 44.2% 5,598
No. individual data values 39,590 88.4% 5,194 11.6% 44,784
Table 3. Imputation models used. Table shows the models used for imputation of the missing data. Data that were not 
imputed were Pregnancy outcomes as these were the primary outcomes; HPV viral/pathological data because these were 
the primary factors of interest; maternal age was complete.
Parameters for which 
missing data was 
imputed
Valid N Missing Imputed 
values
Model
N Percent Type Effects
SIMD 5,562 36 0.6% 180 Logistic 
Regression
Parity, Hypertensive disorder, Current 
smoking, Smoking History, Diabetes, 
Ethnicity, Maternal BMI
Parity 5,504 94 1.7% 470 Logistic 
Regression
SIMD, Hypertensive disorder, Current 
smoking, Smoking History, Diabetes, 
Ethnicity, Maternal BMI
Maternal hypertension 5,484 114 2.0% 570 Logistic 
Regression
SIMD, Parity, Current smoking, 
Smoking History, Diabetes, Ethnicity, 
Maternal BMI
Current Smoking 5,226 372 6.6% 1,860 Logistic 
Regression
SIMD, Parity, Hypertensive disorder, 
Diabetes, Ethnicity, Maternal BMI
Smoking history 5,061 537 9.6% 2,685 Logistic 
Regression
SIMD, Parity, Hypertensive disorder, 
Current smoking, Diabetes, Ethnicity, 
Maternal BMI
Maternal diabetes 4,763 835 14.9% 4,175 Logistic 
Regression
SIMD, Parity, Hypertensive disorder, 
Current smoking, Smoking History, 
Ethnicity, Maternal BMI
Maternal BMI at booking 
(kg/m2)
4,148 1,450 25.9% 7,250 Linear 
Regression
SIMD, Parity, Hypertensive disorder, 
Current smoking, Smoking History, 
Diabetes, Ethnicity
Ethnicity 3,842 1,756 31.3% 8,780 Logistic 
Regression
SIMD, Parity, Hypertensive disorder, 
Current smoking, Smoking History, 
Diabetes, Maternal BMI
together so that any potential interactions could be taken into 
account30. For the logistic regression analyses, pooled results 
from five imputations are presented in the results. The HPV 
viral/pathology parameters (HR HPV, HPV-16/18 genotype, 
HPV-associated cervical disease and HPV vaccination status) 
were not imputed, as these were the primary predictive factors of 
interest for the analyses.
The proportions of maternal characteristics  according to preg-
nancy outcomes or according to HPV viral/pathology param-
eters were compared by chi squared or Fisher’s exact test 
analysis and are shown in Table 4 and Table 5, respectively. 
Binary  logistic regression analysis was used for each pregnancy 
outcome, with women who had had term live births as the com-
parator group and each HPV viral/pathology parameter as the 
predictive factor under analysis. Odds ratios (OR) and 95% con-
fidence intervals (CIs) are presented from unadjusted and adjusted 
models in all women. To investigate the effects of prior HPV 
vaccination, the models were run in vaccine-eligible women, 
with and without vaccination status included. Adjusted models 
used the imputed dataset and adjusted for maternal factors that 
might affect pregnancy outcomes: ethnicity, SIMD, parity, age, 
BMI, diabetes, hypertension and current smoking.
Results
Cohort screening, selection and characteristics
Pregnancy admission records (N=32,520) were received for 
women who had been pregnant and had HPV viral/pathology 
data in the Scottish HPV Archive (N=10,572). After data-
cleaning and exclusions, we had obtained 7,512 pregnancy 
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Table 4. Maternal characteristics (original/imputed data) by pregnancy outcome: Term live birth and 
Any preterm birth. Table shows the numbers and percentages of women in each pregnancy outcome 
group compared by maternal factors that might affect pregnancy outcome. The numbers shown are from 
original data or the imputed data (in italics). Term live births (≥37 weeks gestation) were compared with any 
preterm birth (PTB, <37 weeks gestation). The original (unimputed) data is presented alongside the pooled 
imputed data (italics) to show that the proportions of each parameter are similar between the original 
and imputed datasets, and the imputation process did not adversely skew the data. P values denote 
results from chi squared analysis of the pooled imputed data for each parameter between the two groups. 
Significant p values are highlighted (bold); ns denotes not significant.
Maternal Factor Original data* Pooled imputed data†
Term live births, 
n (%)
Any PTB, 
n (%)
Term live births 
(N=4,942), 
n (%)
Any PTB 
(N=386), 
n (%)
P value
Age (years)‡
Mean age (range) 25 (16–45) 24.6 (17–43) 25 (16–45) 24.6 (17–43)
≤20 years 1082 (21.9) 80 (20.7) 1082 (21.9) 80 (20.7) 0.654
>20 years 3860 (78.1) 306 (79.3) 3860 (78.1) 386 (79.3)
Ethnicity
White 3283 (98.1) 267 (97.4) 4838 (97.9) 377 (97.7) 0.713
Other 64 (1.9) 7 (2.6) 104 (2.1) 9 (2.3)
Parity
Non-parous 3239 (65.9) 259 (67.4) 3256 (65.8) 261 (67.6) 0.504
Parous 1679 (34.1) 125 (32.6) 1686 (34.1) 125 (32.3)
SIMD‖
Most deprived 2464 (50.1) 208 (54.3) 2480 (50.2) 211 (54.7) 0.091
Least deprived 2446 (49.9) 175 (45.7) 2462 (49.8) 175 (45.3)
BMI¶ (kg/m2)
≤19.9 (underweight) 425 (11.0) 47 (17.2) 593 (11.9) 61 (15.8) 0.146
20.0–24.9 (healthy) 1639 (42.5) 115 (42.1) 1981 (40.1) 152 (39.4)
25.0–29.9 (overweight) 1043 (27.1) 57 (20.9) 1387 (28.1) 97 (25.1)
≥30 (obese) 745 (19.3) 54 (19.8) 981 (19.9) 76 (19.6)
Current Smoking
No 3503 (74.1) 235 (64.7) 3642 (73.7) 252 (65.3) <0.001
Yes 1226 (25.9) 128 (35.3) 1300 (26.3) 134 (34.7)
Diabetes#
No 4282 (98.5) 312 (95.7) 4863 (98.4) 370 (95.9)
Any 64 (1.5) 14 (4.3) 79 (1.6) 16 (4.1) 0.002
Hypertension**
No 4563 (92.3) 346 (89.6) 4562 (92.3) 346 (89.6) 0.063
Yes 379 (7.7) 40 (10.4) 380 (7.7) 40 (10.4)
*For the original data, due to missing values, numbers and percentages for each maternal parameter relate to the 
numbers in each analysis and do not add up to the total number of each pregnancy outcome.
†Imputed data are the pooled results of five imputations. The numbers and percentages presented are representative 
of the population as a whole and represent the estimated values that would have been obtained had the dataset been 
complete. Imputed data were used in the logistic regression models.
‡Maternal age was complete. Age range of women in each group is shown.
||Scottish Index of Material Deprivation (SIMD) quintiles were combined as most deprived (quintiles 1 &2) vs. least deprived 
(quintiles 3-5).
¶Body mass index (BMI) was calculated as weight (kg) divided by the square of the patient’s height (m2)
#Diabetes includes gestational diabetes and pre-existing diabetes (Table 1).
**Hypertension did not distinguish between pre-existing or gestational hypertension within SMR02 (Table 1)
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outcomes from 5,626 women (Figure 1). Of these, 32 were 
stillbirths, which, although these had been pre-defined as one 
of the pregnancy outcomes for investigation, were too few for any 
meaningful analysis and were excluded. For the women who had 
had more than one pregnancy, we chose the pregnancy nearest the 
cytology date. The final cohort consisted of 5,598 women.
Women had had term live births (≥37 weeks gestation, n=4942, 
88.3%); all preterm birth (<37 weeks gestation, n=386, 6.9% 
[including those who had a late miscarriage, n=26]) and early 
miscarriage (<13 weeks gestation, n=270, 4.8% [obtained from 
SMR02, n=156, and SMR01, n=114]). On comparison with 
Scottish birth statistics23, the age distribution of the cohort was 
much younger than that of the Scottish childbearing population. 
There were more pregnancy outcomes in women of <25 years 
(62.9%) than in the Scottish population23 (26.5%) and a smaller 
proportion of mothers aged 25–34 years (28.8% vs. 53%) or 
≥35 years (8.3% vs. 20.5%) in our cohort, respectively. The 
percentage of all women who had a preterm birth in our cohort 
(6.9%) was similar to that of the Scottish population23, which 
ranged between 5.8 and 6.7% (between 1999 and 2015). The 
percentage of women having hospital admission for early 
miscarriage in our population was much lower (4.8%) than 
that in the Scottish birth data23. Due to this low rate of miscar-
riage, the miscarriage data were deemed to be problematic due 
to uncertainty in case ascertainment and was thought to not be 
representative of the Scottish child-bearing population. Therefore, 
the results for early miscarriage are not presented.
The characteristics of the women according to the HPV viral/
pathology parameters are shown in Table 5 for the whole cohort. 
The percentage of women with HR HPV-positive results in our 
cohort was 27.5%, which is higher than the HR-HPV prevalence 
(18%) seen previously in the Scottish screening population28, 
probably due to the nature of ‘selective’ sampling in the 
Scottish HPV Archive. Similarly, the percentage of women with 
HPV-16/18 was higher than that in the routine prevalence in 
the same population (9.7% vs. 2.9%, respectively). For HPV- 
associated disease, some women were HR HPV-negative or of 
unknown genotype but showed evidence of HPV-associated 
disease. The proportion of women with low-grade disease was 
higher in our cohort than in the national screening data (16.0% 
vs. 7.5%, respectively) and our cohort had a higher percentage 
of women with high-grade cervical disease (2.9% vs. 1%, 
respectively).
Analysis of the cohort
The numbers and percentages for the maternal factors were 
compared by pregnancy outcomes (term live births vs. all preterm 
birth, Table 4). There were no significant differences in mater-
nal age, ethnicity, parity, SIMD (most vs. least deprived), BMI 
or hypertension between women who had term live births com-
pared with those who had preterm births. A higher proportion 
of all women who had a preterm birth were current smokers 
when compared with those who had term live births (P<0.001). 
Similarly, a higher proportion of all women who had a preterm 
birth also had diabetes than those who had term live birth 
(P=0.063, Table 4).
The numbers and percentages of women in each analysis and the 
unadjusted and adjusted OR from binary logistic regression are 
shown for each HPV viral/pathology parameter and all women who 
had a preterm birth, for all women (Table 6) and vaccine-eligible 
women (Table 7); similarly results for spontaneous preterm birth 
are shown in Table 8 and Table 9.
HR HPV. Binary logistic regression showed that women who 
carried any HR HPV had increased odds of having a preterm 
birth in unadjusted models, but the association was lost in 
adjusted models (Table 6). In vaccine-eligible women there 
was no association between HR HPV and all preterm birth 
and no effect of vaccine (Table 7). Similarly, for spontaneous 
preterm birth, there was no association between HR HPV and 
spontaneous preterm birth in the whole cohort (Table 8), nor 
in vaccine-eligible women and no effect of vaccine (Table 9). 
Current smoking and/or diabetes were independently associated 
with increased odds of all preterm birth and/or spontaneous 
preterm birth. Hypertension was an independent predictor of all 
preterm birth in all women but not vaccine-eligible women.
HR HPV 16/18 types. Only 970 women had known specific 
HR HPV types. There were no associations between carriage of 
HPV16/18 types or non16/non18 HPV types and all preterm 
birth (Table 6 and Table 7) or spontaneous preterm birth 
(Table 8 and Table 9) in the whole cohort nor in vaccine- 
eligible women, and vaccination had no effect. Current smoking 
and/or diabetes were independently associated with increased 
odds of any and/or spontaneous preterm birth. Hypertension 
was an independent predictor of any preterm birth in all women 
but not vaccine-eligible women.
HPV-associated cervical disease. In the whole cohort of 
women, high-grade cervical disease was significantly associated 
with ~80% increased odds of any and spontaneous preterm 
birth (Table 6 and Table 8, respectively) in unadjusted and 
adjusted models of all women. In the vaccine-eligible women 
there were no associations between any level of HPV-associated 
disease and no effect of vaccination in any preterm birth or 
spontaneous preterm birth (Table 7 and Table 9, respectively). 
Current smoking and diabetes were also associated with an 
increased odds of any or spontaneous preterm birth in all 
women. Younger maternal age showed a decreased association 
with HPV-associated cervical disease in the models for both any 
and spontaneous preterm birth.
Discussion
This study found associations between different HPV viral/ 
pathology parameters and adverse pregnancy outcomes. Spe-
cifically, high-grade HPV-associated cervical disease was asso-
ciated with preterm birth and spontaneous preterm birth in the 
whole cohort women, but not in the vaccine-eligible subgroup of 
younger women. No associations were seen between HR HPV- 
positive (with no disease) or low-grade HPV-associated cervical 
disease and all or spontaneous preterm birth.
Associations between high-grade cervical disease and all pre-
term birth or spontaneous preterm birth have been suggested in 
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Table 6. Any preterm birth compared with term live-birth in all women, according to HPV viral/pathological parameters. Table shows 
the pregnancy outcomes: term live births (>37 weeks gestation) and any preterm birth (<37 weeks gestation) compared by each HPV 
parameter for all women in the cohort. The numbers and percentages in each group are shown. The odds ratios (OR) and P values from 
unadjusted and adjusted binary logistic regression models are shown. Significant associations are highlighted in bold.
HPV Parameter Term live birth, n (%)*
Any preterm birth, 
n (%)*
Results from logistic regression models
Unadjusted OR (95% CI) p value Adjusted † OR (95% CI) p value
HR HPV
Negative 2281 (93.3) 165 (6.7) Reference Reference
Positive 1302 (91.4) 122 (8.6) 1.295 (1.015–1.653) 0.037 1.260 (0.985–1.612) 0.066
HPV16/18 type 
HR Negative 2281 (93.3) 165 (6.7) Reference Reference
HPV16/18 471 (91.5) 44 (8.5) 1.291 (0.913–1.827) 0.149 1.255 (0.883–1.784) 0.205
Non16/non18 HR HPV 369 (91.8) 33 (8.2) 1.236 (0.837–1.825) 0.286 1.174 (0.792–1.740) 0.424
HPV-associated 
cervical disease ‡ 
HR negative 2123 (93.3) 153 (6.7) Reference Reference
HR HPV+ve no disease 387 (92.4) 32 (7.6) 1.147 (0.772–1.702) 0.496 1.110 (0.745–1.655) 0.608
Low-grade abnormalities 773 (92.7) 61 (7.3) 1.095 (0.805–1.490) 0.564 1.061 (0.777–1.448) 0.710
High-grade disease 140 (88.1) 19 (11.9) 1.883 (1.135–3.125) 0.014 1.843 (1.101–3.083) 0.020
* Due to missing HPV data, numbers and percentages relate to the numbers that were present in each analysis and do not add up to the total numbers of 
women in each pregnancy outcome.
† Adjusted binary logistic regression models used the imputed dataset and are pooled results from 5 imputations. Models were adjusted for ethnicity, SIMD 
(most deprived vs. least deprived), maternal age, parity, smoker in current pregnancy, diabetes, hypertensive disorder and maternal BMI.
‡ Criteria for HPV-associated cervical disease are shown in the methods and Table 1.
Cofactors that had a significant association with preterm birth from these models were:
HR HPV: Current Smoking OR=1.429 (1.096–1.863) P=0.008; Diabetes OR=2.745 (1.280–5.884) P=0.010; Hypertension OR=1.552 (1.045–2.305) P=0.030.
HR HPV16/18 type: Current Smoking OR=1.367 (1.018–1.836) P=0.038; Diabetes OR=3.243 (1.414–7.441) P=0.006; Hypertension OR=1.609 (1.051–2.462) 
P=0.029.
HPV-associated cervical disease: Current Smoking OR=1.573 (1.193–2.073) P=0.001; Diabetes OR=2.641 (1.271–5.489) P=0.009; Maternal age ≤20 years 
OR=0.686 (0.495–0.950) P=0.023.
previous studies13,14. In this study, such associations were not seen 
in the younger, vaccine-eligible subgroup of women, suggesting 
that the older women were infected for longer and had time to 
develop high-grade cervical disease30. Previous studies showing 
associations between HPV-associated cervical disease and 
preterm birth have been ambiguous regarding whether these 
were due to HPV-infection itself, development of associated CIN 
lesions or the excision of these lesions31,32. Low-grade cervical 
lesions are more likely to be associated with productive 
HPV-infections, where the viral life-cycle is completed, com-
pared with infections associated with severe disease where the 
viral life-cycle is poorly supported33. Productive infections are 
also associated with a peak/burst of viral load over a narrower 
time-frame than infections associated with high-grade disease34. 
Therefore, in the absence of any associations with HR HPV- 
infection alone or low-grade cervical disease, and given that 
over 90% of those who had high-grade disease would have been 
treated4, we suggest that the association with high-grade 
cervical disease, in our cohort, is likely to be due to the treatment 
of HPV-associated cervical disease rather than a direct effect of 
HPV-infection itself. The clinical implication is that women 
who have undergone treatment for HPV-associated cervical 
disease should be closely monitored in subsequent pregnancies for 
any signs of preterm birth.
Although only HPV-associated high-grade cervical disease 
was associated with all preterm birth and spontaneous pre-
term birth, current smoking was consistently associated with 
spontaneous preterm birth. Smoking is a previously recog-
nised risk factor for spontaneous preterm birth35. Diabetes and 
hypertension were also independently associated with all pre-
term birth, but this was not surprising as these are likely to be the 
indicative reasons for early delivery of the baby. A recent study 
suggested that HPV infection in the placenta was associated with 
a number of pregnancy complications36, including gestational 
diabetes. However, our data did not find an increased associa-
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Table 7. Any preterm birth compared with term live-births in vaccine-eligible women, according to HPV viral/pathological 
parameters. Table shows the women with each pregnancy outcome: term live births (>37 weeks gestation) and any preterm birth (<37 
weeks gestation) compared by each HPV parameter for vaccine-eligible women in the cohort. The numbers and percentages in each 
group are shown. The odds ratios (OR) and P values from unadjusted and adjusted binary logistic regression models are shown. Significant 
associations are highlighted in bold.
HPV Parameter
Term live birth*, 
n (%)
Any preterm birth*, 
n (%)
Results from logistic regression
Unadjusted OR (95% CI) p value Adjusted † OR (95% CI) p value
HR HPV
HR HPV negative 1583 (93.2) 115 (6.8) Reference Reference
HR HPV Positive   905 (91.2)   87 (8.8) 1.323 (0.990–1.769) 0.059 1.282 (0.956–1.719) 0.098
With adjustment for 
Vaccination status
HR HPV negative 1583 (93.2) 115 (6.8) Reference Reference
HR HPV Positive   905 (91.2)   87 (8.8) 1.310 (0.943–1.820) 0.108 1.255 (0.899–1.752) 0.182
Unvaccinated 2026 (92.6) 163 (7.4) Reference Reference
Vaccinated   510 (93.4)   36 (6.6) 0.884 (0.591–1.320) 0.545 0.925 (0.613–1.395) 0.710
HPV16/18 type
HR HPV negative 1583 (93.2) 115 (6.8) Reference Reference
HR HP16/18   371 (91.2)   36 (8.8) 1.336 (0.903–1.975) 0.147 1.312 (0.883–1.948) 0.179
Non-16/non18 HR HPV   280 (91.2)   27 (8.8) 1.327 (0.857–2.057) 0.205 1.247 (0.801–1.943) 0.328
With adjustment for 
Vaccination status
HR negative 1583 (93.2) 115 (6.8) Reference Reference
HPV 16/18   371 (91.2)   36 (8.8) 1.282 (0.859–1.912) 0.224 1.252 (0.836–1.875) 0.276
Non16/non18 HR HPV   280 (91.2)   27 (8.8) 1.349 (0.863–2.109) 0.188 1.260 (0.801–1.982) 0.318
Unvaccinated 2026 (92.6) 163 (7.4) Reference Reference
Vaccinated   510 (93.4)   36 (6.6) 0.879 (0.587–1.317) 0.533 0.925 (0.611–1.399) 0.710
HPV-associated Cervical 
Disease‡§
HR negative 1464 (93.2) 107 (6.8) Reference Reference
HR HPV+ve no disease   236 (91.5)   22 (8.5) 1.275 (0.790–2.059) 0.319 1.251 (0.772–2.029) 0.363
Low-grade abnormalities   561 (93.0)   42 (7.0) 1.024 (0.708–1.483) 0.899 0.980 (0.674–1.426) 0.918
High-grade disease      -- (89.0)   -- (11.0) 1.710 (0.761–3.844) 0.194 1.577 (0.693–3.586) 0.277
With adjustment for 
Vaccination status
HR negative 1464 (93.2) 107 (6.8) Reference Reference
HR HPV+ve no disease   236 (91.5)   22 (8.5) 1.275 (0.754–2.158) 0.365 1.223 (0.718–2.084) 0.458
Low-grade abnormalities   561 (93.0)   42 (7.0) 0.989 (0.600–1.629) 0.965 0.935 (0.564–1.549) 0.793
High-grade disease      -- (89.0)   -- (11.0) 1.673 (0.741–3.799) 0.216 1.506 (0.655–3.463) 0.335
Unvaccinated 2026 (92.6) 163 (7.4) Reference Reference
Vaccinated   510 (93.4)   36 (6.6) 0.823 (0.518–1.308) 0.410 0.863 (0.538–1.386) 0.543
* Due to missing HPV data, numbers and percentages relate to the numbers that were present in each analysis and do not add up to the total numbers in each 
pregnancy outcome.
† Adjusted binary logistic regression models used the imputed dataset and are pooled results from 5 imputations. Models were adjusted for ethnicity, SIMD 
(most deprived vs. least deprived), maternal age, parity, smoker in current pregnancy, diabetes, hypertensive disorder and maternal BMI.
‡ Criteria for HPV-associated cervical disease are shown in the methods and Table 1.
§ Where there were groups containing <10 women, the numbers were not released from the Safe Haven and only the percentages are given.
Cofactors that had a significant association with preterm birth from these models were:
HR HPV: without adjustment for vaccination Diabetes OR=3.552 (1.495–8.442), P=0.004; with adjustment for vaccination Diabetes OR=4.479 (1.834–10.94) 
P=0.001.
HR HPV16/18 type: without adjustment for vaccination Diabetes OR=4.158 (1.714–10.09) P=0.002; with adjustment vaccination Diabetes OR=4.478 (1.832–
10.95) P=0.001.
HPV-associated cervical disease: without adjustment for vaccination Diabetes OR=3.529 (1.479–8.422) P=0.004; with adjustment for vaccination Diabetes 
OR=4.992 (1.999–12.46) P=0.001, Maternal age ≤20 years OR=0.669 (0.448–0.998) P=0.049.
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Table 8. Spontaneous preterm birth compared with term live-birth in all women, according to HPV viral/pathological parameters. 
Table shows the women who had pregnancy outcomes: term live births (>37 weeks gestation) and spontaneous preterm birth (<37 weeks 
gestation) compared by each HPV parameter for all women. The numbers and percentages in each group are shown. The odds ratios (OR) 
and P values from unadjusted and adjusted binary logistic regression models are shown. Significant associations are highlighted in bold.
HPV Parameter Term live birth, n (%)*
Any preterm birth, 
n (%)*
Results from logistic regression models
Unadjusted OR (95% CI) p value Adjusted † OR (95% CI) p value
HR HPV
Negative 2281 (94.2) 140 (5.8) Reference Reference
Positive 1302 (93.0)   98 (7.0) 1.226 (0.939–1.602) 0.134 1.189 (0.908–1.556) 0.209
HPV16/18 type
HR Negative 2281 (94.2) 140 (5.8) Reference Reference
HPV16/18   471 (93.1)   35 (6.9) 1.291 (0.825–1.777) 0.328 1.169 (0.794–1.723) 0.429
Non16/non18 HR HPV   369 (92.7)   29 (7.3) 1.280 (0.846–1.939) 0.243 1.220 (0.803–1.854) 0.352
HPV-associated 
cervical disease ‡
HR negative 2123 (94.2) 130 (5.8) Reference Reference
HR HPV+ve no disease   387 (93.3)   28 (6.7) 1.182 (0.774–1.803) 0.439 1.141 (0.746–1.746) 0.544
Low-grade abnormalities   773 (93.9)   50 (6.1) 1.056 (0.755–1.479) 0.750 1.015 (0.723–1.426) 0.930
High-grade disease   140 (89.7)   16 (10.3) 1.866 (1.080–3.224) 0.025 1.791 (1.028–3.121) 0.040
* Due to missing HPV data, numbers and percentages relate to the numbers that were present in each analysis and do not add up to the total numbers in each 
pregnancy outcome.
† Adjusted binary logistic regression models used the imputed dataset and are pooled results from 5 imputations. Models were adjusted for ethnicity, SIMD 
(most deprived vs. least deprived), maternal age, parity, smoker in current pregnancy, diabetes, hypertensive disorder and maternal BMI. Any cofactors that 
had a significant association with preterm birth from these models are shown.
‡ Criteria for HPV-associated cervical disease are shown in the methods.
Cofactors that had a significant association with preterm birth from these models were:
HR HPV: Current smoking OR=1.448 (1.079–1.942), P=0.014
HR HPV16/18 type: Current Smoking OR=1.445 (1.050–1.990), P=0.024
HPV-associated cervical disease: Current Smoking OR=1.599 (1.182–2.162) P=0.002; Diabetes OR=2.499 (1.088–5.738) P=0.031; Maternal Age ≤20 years 
OR=0.662 (0.464–0.945) P=0.023.
Table 9. Spontaneous preterm birth compared with term live-births in vaccine-eligible women, according to HPV viral/pathological 
parameters. Table shows the pregnancy outcomes term live births (>37 weeks gestation) and spontaneous preterm birth (<37 weeks 
gestation) compared by each HPV parameter for vaccine-eligible women. The numbers and percentages in each group are shown. The 
odds ratios (OR) and P values from unadjusted and adjusted binary logistic regression models are shown. Significant associations are 
highlighted in bold.
HPV Parameter Term live birth*, n (%)
Any preterm birth*, 
n (%)
Results from logistic regression
Unadjusted OR (95% CI) p value Adjusted † OR (95% CI) p value
HR HPV
HR HPV negative 1583 (94.3)   95 (5.7) Reference Reference
HR HPV Positive   905 (93.0)   68 (7.0) 1.252 (0.907–1.727) 0.171 1.210 (0.874–1.674) 0.251
With adjustment for 
Vaccination status
HR HPV negative 1583 (94.3)   95 (5.7) Reference Reference
HR HPV Positive   905 (93.0)   68 (7.0) 1.300 (0.908–1.862) 0.151 1.256 (0.874–1.806) 0.218
Unvaccinated 2026 (93.5) 140 (6.5) Reference Reference
Vaccinated   510 (95.1)   26 (4.9) 0.740 (0.467–1.174) 0.202 0.756 (0.472–1.211) 0.244
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HPV Parameter Term live birth*, n (%)
Any preterm birth*, 
n (%)
Results from logistic regression
Unadjusted OR (95% CI) p value Adjusted † OR (95% CI) p value
HPV16/18 type
HR HPV negative 1583 (94.3)   95 (5.7) Reference Reference
HR HP16/18   371 (93.0)   28 (7.0) 1.258 (0.813–1.946) 0.303 1.230 (0.792–1.910) 0.358
Non-16/non18 HR HPV   280 (92.1)   24 (7.9) 1.428 (0.897–2.275) 0.133 1.348 (0.843–2.155) 0.213
With adjustment for 
Vaccination status
HR negative 1583 (94.3)   95 (5.7) Reference Reference
HPV 16/18   371 (93.0)   28 (7.0) 1.179 (0.754–1.843) 0.470 1.156 (0.737–1.814) 0.528
Non16/non18 HR HPV   280 (92.1)   24 (7.9) 1.474 (0.917–2.370) 0.109 1.396 (0.864–2.256) 0.173
Unvaccinated 2026 (93.5) 140 (6.5) Reference Reference
Vaccinated   510 (95.1)   26 (4.9) 0.725 (0.455–1.154) 0.175 0.742 (0.461–1.193) 0.218
HPV-associated Cervical 
Disease ‡ §
HR negative 1464 (94.3)   88 (5.7) Reference Reference
HR HPV+ve no disease   236 (92.5)   19 (7.5) 1.339 (0.801–2.241) 0.266 1.319 (0.785–2.216) 0.295
Low-grade abnormalities   561 (94.3)   34 (5.7) 1.008 (0.671–1.516) 0.968 0.959 (0.635–1.449) 0.843
High-grade disease    -- (90.3)    -- (9.7) 1.782 (0.748–4.250) 0.192 1.625 (0.673–3.922) 0.280
With adjustment for 
Vaccination status
HR negative 1464 (94.3)   88 (5.7) Reference Reference
HR HPV+ve no disease   236 (92.5)   19 (7.5) 1.372 (0.785–2.397) 0.267 1.326 (0.755–2.330) 0.327
Low-grade abnormalities   561 (94.3)   34 (5.7) 1.126 (0.671–1.888) 0.654 1.066 (0.632–1.798) 0.812
High-grade disease   -- (90.3)    -- (9.7) 1.687 (1.704–4.041) 0.241 1.518 (0.622–3.701) 0.359
Unvaccinated 2026 (93.5) 140 (6.5) Reference Reference
Vaccinated   510 (95.1)   26 (4.9) 0.689 (0.407–1.168) 0.167 0.719 (0.420–1.231) 0.229
* Due to missing HPV data, numbers and percentages relate to the numbers that were present in each analysis and do not add up to the total numbers in each 
pregnancy outcome.
† Adjusted binary logistic regression models used the imputed dataset and are pooled results from 5 imputations. Models were adjusted for ethnicity, SIMD 
(most deprived vs. least deprived), maternal age, parity, smoker in current pregnancy, diabetes, hypertensive disorder and maternal BMI. Any cofactors that 
had a significant association with preterm birth from these models are shown.
‡ Criteria for HPV-associated cervical disease are shown in the methods.
§ Where there were groups containing <10 women, the numbers were not released from the Safe Haven and only the percentages are given.
Cofactors that had a significant association with preterm birth from these models were:
HR HPV: without adjustment for vaccination status there were no significant cofactors; with adjustment for vaccination status Diabetes OR=3.190 (1.054–9.652) 
P=0.040
HR HPV16/18 type: without adjustment for vaccination status there were no significant cofactors; with adjustment for vaccination status Diabetes OR=3.165 
(1.045–9.586), P=0.042.
HPV-associated cervical disease: without adjustment for vaccination Diabetes OR=3.113 (1.146–8.456) P=0.026; with adjustment for vaccination status 
Diabetes OR=4.270 (1.513–12.05) P=0.006
tion between HPV viral/pathology data and diabetes and so do 
not support such an association.
There are strengths and weaknesses for this study. The strengths 
of this study are that this was a data linkage study starting with 
women for whom HPV-infection status was known. The use 
of the Scottish HPV Archive meant that the HPV viral/pathology 
parameters for these women had been robustly characterised and 
the HPV information was not available from any other source. 
The use of routinely collected data should also reduce bias in the 
recording of clinical information. Primary HPV screening in 
Scotland will soon include results from HPV testing. Such 
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information may facilitate a future population-wide analysis 
of the effects of HPV-infection and pregnancy outcomes in the 
Scottish population.
A weakness of the study is that we did not have details of any 
treatments for cervical disease, so we have had to rely on an 
assumption that women with high-grade disease received exci-
sional treatment as per national guidelines. The age-distribution 
of the women did not reflect that of the Scottish childbearing 
population23, and therefore, it is hard to determine how repre-
sentative these results are of the wider population. The study 
cohort was drawn from the general population by the fact that 
they underwent cervical screening, but were considerably younger 
at pregnancy outcome and had higher proportions of women 
with HPV-infection and HPV-associated cervical disease, due 
to the selective nature of the samples within the Scottish HPV 
Archive. The preterm birth rates were similar to that in the 
Scottish population. The early miscarriage data were obtained 
from maternity/hospital admission records, but would not 
include miscarriages managed at home, through outpatient and 
emergency departments or by General Practitioners. The risk 
of miscarriage increases with age, particularly after the age 
of 40 years, although a slightly increased risk of miscarriage 
exists in women aged under 20 years38. The miscarriage rate 
in our population was much lower than the that reported for 
miscarriages managed in hospitals23. While this lower rate may 
particularly reflect the youth of our cohort, the differences are 
hard to explain, and so these data were not presented.
In summary, our data linkage study has found no evidence that 
HPV infection per se, or low-grade HPV-associated cervical 
disease was associated with preterm birth. High-grade disease, 
the majority of which is treated with excisional treatments, was 
associated with spontaneous preterm birth. This is consistent 
with previous evidence linking excisional cervical treatment 
with increased risk of spontaneous preterm birth13.
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be defined in the methods section.
I found Table 5 very confusing, particularly with respect to vaccination status compared to HPV
viral/pathology parameters. The statistically significant results may need to be spelled
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treatment does not influence pregnancy outcomes .
There is growing evidence that observational management for low and intermediate grade cervical
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